APSR2026-656

 
Late-Breaking
Submitted
Oral Presentation
AO33-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1221057-46903-YU_BCB APSR 2026 oral presentation _433920.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Beverly Christine Yu * Philippine General Hospital Division of Pulmonary Medicine, Department of Internal Medicine Manila Philippines
Gene Philip Louie Ambrocio - Philippine General Hospital Division of Pulmonary Medicine, Department of Internal Medicine Manila Philippines
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Beverly Christine
Yu
bcyu96@gmail.com
+639273831587
Under 30
Philippines
Original Research
The Safety and Efficacy of N-acetylcysteine in the prevention of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis
Maximum 25 words
Abstract Content
Anti-tuberculosis Drug-induced liver injury (AT-DILI) is a major cause of treatment interruption in the management of tuberculosis. There are currently no recommended preventive agents for AT-DILI but there are available studies suggesting that N-acetylcysteine (NAC) can help reduce oxidative stress by replenishing cellular glutathione stores. This study aims to evaluate the safety and efficacy of NAC in preventing AT-DILI in patients undergoing standard TB treatment.
A literature search was conducted in PubMed, Embase, and Cochrane Library through February 2026 for randomized controlled trials (RCTs) evaluating the addition of NAC to the standard TB regimen. Pooled risk ratios and mean differences were computed using a random-effects model. The study was registered in PROSPERO (CRD420261300596)
A total of Four RCTs (N=407) were included in the analysis. NAC supplementation was associated with a significant reduction in the risk of AT-DILI (RR 0.17; 95% CI: 0.04–0.80; p=0.03). In a subgroup analysis only including data from countries with a known high prevalence of slow acetylators, NAC supplementation was associated with a higher reduction in the risk of AT-DILI (RR 0.07; 95% CI: 0.02-0.30; p=0.0003). NAC significantly reduced mean AST levels (MD -33.96; 95% CI: -57.11 to -10.81; p=0.004) and mean ALT levels (MD -40.21; 95% CI: -65.31 to -15.10; p=0.002) after two weeks of NAC supplementation when compared to control. Addition of NAC to standard TB regimen was also well-tolerated, with no significant difference in adverse events compared to control (RR 1.18; 95% CI: 0.73–1.91; p=0.51)
The addition of NAC to standard TB regimen significantly reduces the incidence of AT-DILI and lowers AST and ALT levels without increasing adverse event rates. NAC represents a promising, safe adjunctive therapy to improve TB treatment completion, especially in populations with a high prevalence of slow acetylators.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Tuberculosis, N-acetylcysteine, Drug induced liver injury
maximum 3 keywords and no abbreviations, separated by commas
NA
316